La Valbiotis fait son entrée sur Euronext Growth

€11.5 million raised; market capitalisation above €37 million

Paris – 7 June 2017 – Euronext today welcomes Valbiotis, a company specialised in research and development in medical nutrition, to its Euronext Growth[1] market in Paris.

An innovative company based in La Rochelle, Valbiotis develops nutrition solutions to prevent cardio metabolic diseases and provides nutritional support for affected patients. Its plant-based products are scientifically and clinically developed for manufacturers in the agro-food and pharmaceutical industries. The company works alongside academic research centres of excellence to help fight against diabetes, obesity, cardio-vascular disease and non-alcoholic steato-hepatitis (NASH).

Valbiotis (ticker code: ALVAL) was listed through the admission to trading on June 7, 2017 of 3 547 936 shares including 1 095 238 new shares issued through a Global Offering^{^[2]} including the extension option.

The offering price was set at €10,5 per share. Market capitalisation was above €37 million on the day of listing, and the transaction raised a total of €11.5 million.

Sébastien Peltier, Chairman and CEO of Valbiotis, said: “We are very proud to announce our successful listing today on Euronext Growth, and would like to thank all of the shareholders and investors—French and international individuals and institutions—that have given us their trust and support. Listing is a key step in our development, and the funds raised will enable Valbiotis to step up the pace of its pre-clinical and clinical programs. We will also be able to bring our technical platform and external partners in-house, and accelerate our search for partnerships with leading players in the pharmaceutical and food industries.”

Euronext is now Europe’s leading stock exchange for the listings of European technology companies, covering a wide range of sectors from digital to software, media and eco-industries. With today’s listing, Valbiotis joins the family of 81 life sciences SMEs already listed on Euronext, which together represents a total capitalisation of nearly €13 billion.

_{[1] The « Alternext » market will become « Euronext Growth » from 19 June 2017.}

_{[2] The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.}

Press Release Footer

About Euronext
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €7.1 trillion in market capitalisation as of end March 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

_{Disclaimer

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.}

_{This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.}